J Rheum Dis.  2022 Oct;29(4):191-192. 10.4078/jrd.22.0034.

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?

• Jeon CH

• KMID: 2533619
• DOI: http://doi.org/10.4078/jrd.22.0034

Reference

1. Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. 2019; Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey. J Rheumatol. 46:564–71. DOI: 10.3899/jrheum.180668. PMID: 30647170.

2. Joo YB, Jeong SM, Park YJ, Kim KJ, Park KS. 2022; Use of disease-modifying antirheumatic drugs after cancer diagnosis in rheumatoid arthritis patients. J Rheum Dis. 29:162–70. DOI: 10.4078/jrd.2022.29.3.162.

3. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. 2015; Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 17:212. DOI: 10.1186/s13075-015-0728-9. PMID: 26271620. PMCID: PMC4536786.

4. De Cock D, Hyrich K. 2018; Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. Best Pract Res Clin Rheumatol. 32:869–86. DOI: 10.1016/j.berh.2019.03.011. PMID: 31427060.

5. Warren GW, Cummings KM. 2013; Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book. 33:359–64. DOI: 10.14694/EdBook_AM.2013.33.359. PMID: 23714547.

6. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. 2010; Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 69:70–81. DOI: 10.1136/ard.2008.096487. PMID: 19174392.

7. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. 2006; Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54:692–701. DOI: 10.1002/art.21675. PMID: 16508929.

8. Coussens LM, Werb Z. 2002; Inflammation and cancer. Nature. 420:860–7. DOI: 10.1038/nature01322. PMID: 12490959. PMCID: PMC2803035.

9. Pundole X, Suarez-Almazor ME. 2020; Cancer and rheumatoid arthritis. Rheum Dis Clin North Am. 46:445–62. DOI: 10.1016/j.rdc.2020.05.003. PMID: 32631599.

10. Kim SC, Pawar A, Desai RJ, Solomon DH, Gale S, Bao M, et al. 2019; Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. 49:222–8. DOI: 10.1016/j.semarthrit.2019.03.002. PMID: 30967248.

11. Wadström H, Frisell T, Askling J. Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. 2017; Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 177:1605–12. DOI: 10.1001/jamainternmed.2017.4332. PMID: 28975211. PMCID: PMC5710271.

12. Sivaraman P, Cohen SB. 2017; Malignancy and Janus kinase inhibition. Rheum Dis Clin North Am. 43:79–93. DOI: 10.1016/j.rdc.2016.09.008. PMID: 27890175.

13. Xie W, Xiao S, Huang Y, Sun X, Gao D, Ji L, et al. 2020; A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford). 59:930–9. DOI: 10.1093/rheumatology/kez475. PMID: 31620795.

14. Regierer AC, Strangfeld A. 2018; Rheumatoid arthritis treatment in patients with a history of cancer. Curr Opin Rheumatol. 30:288–94. DOI: 10.1097/BOR.0000000000000492. PMID: 29389831.

15. Wong PKK, Bagga H, Barrett C, Chong G, Hanrahan P, Kodali T, et al. 2018; A practical approach to the use of conventional synthetic, biologic and targeted synthetic disease modifying anti-rheumatic drugs for the treatment of inflammatory arthritis in patients with a history of malignancy. Curr Rheumatol Rep. 20:64. DOI: 10.1007/s11926-018-0774-9. PMID: 30173305.

16. Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR, Qi SR, Zamora NV, Sharma R, et al. 2020; Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Arthritis Care Res (Hoboken). 72:309–18. DOI: 10.1002/acr.23865. PMID: 30821928.